Ondansetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the central chemoreceptor trigger zone and on peripheral vagal afferents. This inhibition stops serotonin‑mediated stimulation of the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The specific dose and dosing schedule of Ondansetron Kabi are determined by the prescribing clinician based on the indication, patient age, weight, renal and hepatic function, and other individual factors. Healthcare professionals should follow local prescribing guidelines and adjust as needed.

Ondansetron should be used in pregnancy or while breastfeeding only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians typically assess the severity of nausea against available safety data and consider alternative therapies when appropriate.

To request Ondansetron Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other anti‑emetic classes such as dopamine antagonists or antihistamines, ondansetron offers a targeted mechanism by blocking 5‑HT3 receptors, providing superior control of chemotherapy‑induced nausea and vomiting. It generally has a more favourable side‑effect profile, though QT prolongation requires careful monitoring in high‑risk patients.

Ondansetron Kabi tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Ondansetron Kabi is supplied as oral tablets that are taken with or without food, as directed by the prescriber. The tablet is swallowed whole and not intended for crushing or chewing unless specifically advised by a healthcare professional.

The most serious risks include QT interval prolongation, which can lead to potentially life‑threatening cardiac arrhythmias, and severe allergic reactions such as anaphylaxis. Patients with known cardiac conduction disorders or electrolyte abnormalities should be monitored closely.

Ondansetron Kabi is contraindicated in patients with known hypersensitivity to ondansetron or any component of the formulation. It should also be avoided in individuals taking apomorphine due to the risk of severe hypotension, and in patients with a history of significant QT prolongation unless benefits outweigh risks.